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In recent years, the concept of controlled release of encapsulated ingredients at the right place and the 
right time has become of more interest to the food and pharmaceutical industry. Whey proteins are valu-
able by-products from the cheese industry. The physicochemical properties of the whey proteins sug-
gest that they may be suitable for novel food and drug delivery system. The objective of this study was 
to characterize the two step desolvation process of -lactalbumin for preparation of its nanoparticles. 
Following the desolvation of the protein with acetone, the produced nanoparticles were stabilized and 
cross linked by addition of glutaraldehyde. Nanoparticle sample was subsequently purified by 3 cycle’s 
centrifugation (15000 ×g, 20 min). Three process parameters were examined to achieve a suitable size of 
nanoparticles including the pH value, temperature and desolvating agent type. In addition, fabricated na-
noparticles were analyzed by photon correlation spectroscopy (PCS) as well as scanning electron mi-
croscopy (SEM). The smallest size of the nanoparticles achieved was 102 nm while the largest size was 
454 nm.  
 





Over the past three decades, considerable research in-
terest has risen worldwide in the development of new col-
loidal drug delivery systems. The ideal colloidal delivery 
system would transport the associated drug to its desired 
site of action and then release it at an optimum rate. The 
carrier itself should be non-toxic and able to be degraded 
in vivo so that it dose not accumulate indefinitely in the 
tissues (Panyam and Labhasetwar, 2003). These delivery 
systems offer numerous advantages compared to con-
ventional dosage forms which include improved effi-
ciency, reduced toxicity and improved patient compliance 
and convenience.  
To convey a sufficient dose of drug to the lesion, suit-
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particles have emerged as versatile systems for the spe 
cific delivery of drugs to organs and tissues (Langer et 
al., 2008). Nanoparticles are colloidal particles which are 
less than 1 µm in diameter. In colloidal system, the size 
of particle is very important in distribution of drug in hu-
man body (Rahimnejad et al., 2006). Nanoparticles have 
the unique property to accumulate at the site of inflamma-
tion and therefore, are very suitable for targeted drug de-
livery. The selection of matrix materials is dependent on 
many factors including: (a) Size of nanoparticles required; 
(b) inherent properties of the drug, for example, aqueous 
solubility and stability; (c) surface characteristics such as 
charge and permeability; (d) degree of biodegradability, 
biocompatibility and toxicity; (e) drug release profile de-
sired; and (f) antigenicity of the final product (Jahanshahi 
and Babaei, 2008).  
Nonoparticles are normally made from synthetic or natu-
ral polymers. The polymers used may also be either bio-
degradable or nonbiodegradable. An ideal polymer 





pyrogenic and with minimum or no toxicity. The polymer 
should also have a high capacity to accommodate the 
drugs and protect them from degradation until they are 
delivered to the target site. Natural polymers have the 
distinct advantages of biodegradability and lack of toxic-
ity, but suffer from reproducibility and well defined phys-
ico-chemical properties. 
Polymeric nanoparticles have attractive physicochemi-
cal properties such as size, surface potential, hydro-
philic-hydrophobic balance etc, and for this reason they 
have been recognizes as potential drug carrier for bioac-
tive ingredient such as anticancer drugs, vaccines, oli-
gonucleotides, peptides, etc (Jahanshahi et al., 2008b). 
The major advantage of colloidal drug carrier systems 
is the possibility of drug targeting by a modified body 
distribution as well as the enhancement of the cellular 
uptake of a number of substances. Among these colloi-
dal systems those based on proteins may be very prom-
ising, since they are biodegradable and non-antigenic, 
relatively easy to prepare and their size distribution can 
be monitored easily (Weber et al., 2000).  
Nanomaterials derived from proteins, especially protein 
nanoparticles are biodegradable, non-antigenic, metabo-
lizable and can also be easily amenable for surface 
modification and covalent attachment of drugs and li-
gands. Because of the defined primary structure of pro-
teins, the protein-based nanoparticles may suggest vari-
ous possibilities for surface alteration and covalent drug 
attachment (Weber et al., 2000). In fact protein is bio-
polymer which is commonly used for preparation of 
nanostructured molecules for drug delivery.  
In spite of successful elaboration of many synthetic po-
lymers as delivery systems, these cannot be used in 
food applications that require compounds generally rec-
ognized as safe (GRAS). Food biopolymers, specifically 
food proteins are widely used in formulate food because 
they have high nutritional value and are generally recog-
nized as safe. Food proteins show great promise for 
developing and engineering a range of new GRAS matri-
ces with the potential to incorporate nutraceutical com-
pound and provide controlled release via the oral route. 
Clear advantages of food protein matrices include their 
high nutritional value, abundant renewable sources and 
acceptability as naturally occurring food components 
degradable by digestive enzymes.  
The ability to control the particle size of proteinaceous 
materials is of primary importance not only for determin-
ing food products properties such as taste, aroma, tex-
ture and appearance, but also for determining the re-
lease rates of the carried bioactive compounds and ulti-
mately how much is absorbed into the body and hence 
the overall efficacy of the compounds (Chen et al., 
2006). Protein based nanoparticles have found wide and 
rapidly increasing application in the food industry be-
cause they can be precisely designed for use in many 
food formulations and virtually any ingredient can be 
encapsulated whether hydrophobic,  hydrophilic  or  even  





Due to their sub-cellular size, nanoparticles offer prom-
ising means of improving the bioavailability of nutraceutical 
compounds, especially poorly soluble substance such as 
functional lipids (carotenoids, phytosterols, -3 fatty ac-
ids), natural antioxidants and numerous other compounds 
that are widely used as active ingredients in various food 
products. They can dramatically prolong compound resi-
dence time in the gastro-intestinal (GI) tract by decreasing 
the influence of intestinal clearance mechanisms and in-
creasing the surface available to interact with the biological 
support (Kavashim, 2001; Peppas, 1995; Arbos et al., 
2002). They can also penetrate deeply into tissues through 
fine capillaries, cross the epithelial lining fenestration (e. g. 
in the liver) and are generally taken up efficiency by cells, 
thus, allowing efficient delivery of active compounds to 
target sites in the body (Chen et al., 2006).  
There are two categories of milk protein in the milk - 
whey and casein proteins. Whey proteins (WP) are impor-
tant food ingredients that are used in a number of food 
products that include dairy products, confectionary and 
desserts. WP composes about 20% of bovine milk and is 
generally produced as a co-product of the cheese industry. 
The utilization of WP has been an important research 
focus over the past few decades because of its abundance 
and excellent nutritional value (DeWit et al., 1984; Tziboula 
et al., 1998; Muir et al., 1984).  
-Lactalbumin is the major whey protein found in milk. 
-Lactalbumin is a protein present in the milk of all mam-
mals. The molecular weight is 14176 Da and the iso-
electric point is between 4.2 and 4.5. In addition, -lactal-
bumin has significant nutritional properties and is associ-
ated with some positive health effects upon consumption. 
-Lactalbumin has an important function in mammary 
secretary cells: it is one of the two components of the lac-
tose biosynthesis in the lactating mammary gland. Its ami-
no acid composition seems to be optimal for the require-
ments of the infant and it has a high digestibility. It is rela-
tively rich in tryptophan (four residues per molecule) and -
lactalbumin consumption increase plasma tryptophan 
which is known to have a positive effect on satiety and 
mood. Evening consumption of -lactalbumin was shown 
to increase plasma tryptophan availability and improved 
morning alertness and brain-sustained attention proc-
esses.  
In other studies, -lactalbumin consumption was shown 
to improve mood and cognitive performance in vulnerable 
subjects. -lactalbumin itself (or its fragments) possesses 
bacterial or antitumor activity (Graveland-Bikker and de 
Kruif 2006). It can be used as a basis for design of antitu-
mour agent, acting through disorganization of chromatin 
structure due to electrostatic interaction between -lactal-
bumin and histone proteins (Permyakov et al., 2004).  
In addition, synthesis of nanoparticles has been at-
tempted using various methods based on physical and 
chemical processes. Basically three different preparation 
of such  nanoparticles  (protein  nanoparticles)  have  been 




described based on emulsion formation, desolvation or 
coacervation (Jahanshahi et al., 2008a). The disadvan-
tage of the emulsion methods for particle preparation is 
the need for applying organic solvents for the removal 
both of the oily residues of the preparation process and of 
surfactants required for emulsion stabilization.  
Therefore, as an alternative method for the preparation 
of nanoparticles as desolvation process derived from 
coacervation method of micro encapsulation was devel-
oped. Protein nanoparticle has been extensively studied 
in our previous work and gradually fabrication process 
have been developed (Rahimnejad et al., 2006; Jahan-
shahi et al., 2008a, b).   
In this work, simple coacervation method is used for 
manufacturing -lactalbumin nanoparticles as a drug and 
food delivery systems and the essential parameters are 
considered. Investigations are focused on the influence of 
pH value, temperature and desolvating agent upon the 
produced nanoparticle size. 
 
 




-Lactalbumin (purity > 85%) and glutaraldehyde (25% solution) 
were commercially supplied by Sigma Aldrich. Acetone and all other 
chemicals were supplied from Merck (Germany). 
 
 
Preparation of -lactalbumin nanoparticles 
 
Two-step desolvation technique was implemented for preparation of 
-lactalbumin nanoparticles. 25 mg.ml-1 aqueous solution of -
lactalbumin was stirred on 500 rpm magnetic stirrer at 50°C for 10 
min. and then 4 ml acetone (desolvating agent), all at once was 
added to cause sedimentation of high molecular weight (HMW) 
component of -lactalbumin. The first step is performed to discard 
low molecular weight (LMW) component of -lactalbumin which 
would make the production of stable nanoparticles with a uni-model 
size distribution impossible.  
After 24 h incubation at room temperature and resolvation of se-
diment in 1 ml purified water and pH-adjustment (pH 2.5), acetone 
was added drop-wise until the solution become just turbid. After 
desolvation process, 30 l of 25% glutaraldehyde was added for 
cross linking and stirred continuously at room temperature for 12 h. 
The formed nanoparticles were purified by 3 cycles of centrifuga-
tion. For each centrifugation step, supernatant was centrifuged at 
15000 g for 20 min. Shape and morphology of -lactalbumin nano-
particles were determined by scanning electron microscopy (SEM). 
 
 
Determination of nanoparticle size and distribution 
 
The size distribution of the prepared -lactalbumin nanoparticle was 
analyzed by photon correlation spectroscopy (PCS), (SALD-2101, 
Japan). PCS is industrially preferred method of sub-micron particle 
size analysis. The sample analyzed in the PCS device should con-
sist of well dispersed particles in liquid medium. In such condition 
the particles are in constant random motion, referred to as Brow-
nian motion and PCS measures the speed of this motion by pass-
ing a laser. PCS determines the average particle size and polydis-
persity Index (PI) which is a range of measurement of the particle 





particle size must be below 0.7 (70%). 
 
 
Scanning electronic microscopic (SEM) 
 
For electronic microscopic scanning micrographs, samples were 
taken from nanoparticles that were experimentally obtained. The 
samples were dipped into liquid nitrojen for 10 min, then freeze 
dried for 7 h in the freeze drier, EMITECH, model IK750, Cambridg, 
UK. The sample was fixed on the aluminium stub and coated with 
gold palladium by Polaron machin model SD515, EMITECH, Cam-
bridg, UK, at 20 nm coating thickness. Finally the sample was ex-
amined under SEM using Stereoscan model S360 brand SEM – 
Leica Cambridg, Cambridg, UK. 
 
 
RESULTS AND DISCUSSION 
 
The nanoparticle sample was analyzed by scanning elec-
tron microscopy (SEM) and photon correlation spectros-
copy (PCS). The morphology and size distribution of pre-
pared nanoparticles from -lactalbumin were examined 
with SEM. Figure 1 shows the particle size with magnifi-
cation of 10000. The shape of the nanoparticles demon-
strated in SEM is semi-spherical.   
In our experiments, we studied the effects of varying 
production parameters on the nanoparticle size. Different 
synthesis parameters were changed, including pH value, 
temperature and desolvating agent type. The goal was to 
prepare small nanoparticles with a narrow size distribu-
tion. It has been shown that, particle size has a great im-
pact on the uptake of nanoparticles. Desai and co-
workers (Amidon, 1997) showed that 100 nm size 
nanoparticles had 2.5 fold greater uptakes compared to 1 
µm and 6 fold higher uptakes compared to 10 µm mi-
croparticles in a Caco-2 cell line.  
The results of other researchers also showed that par-
ticle size significantly affects cellular and tissue uptake 
and in some cell lines, only the submicron size particles 
are taken up efficiently in lieu of the larger size micropar-
ticles (Desai et al., 1996; Zauner et al., 2001). We inves-
tigated the effect of these different parameters on the 
particle size and the polydispersity index where the 
polydispersity index measures the second moment of the 
size distribution of the nanoparticle population. A lower 
polydispersity index indicates a narrower size distribution. 
In order to evaluate the effects of desolvating agent 
type, acetone and ethanol were employed. In these ex-
periments the temperature was kept constant at 50°C 
and 30 µL of glutaraldehyde was added as cross-linking 
agent. The results are shown in Table 1. The results 
show that acetone was the preferred desolvating agent 
as the nanoparticles prepared with acetone were gener-
ally smaller compared to those prepared with ethanol. 
The pH value of the -lactalbumin influenced the result-
ing particle size. The effect of pH on nanoparticle size 
was conducted and shown in Figure 2. Decreasing pH 
will also decrease on the particle size. Therefore, the par-
ticle size is defined in the range of 102 to 454 nm. The re-
sults   showed   that   pH 2.5   was   the  optimum  pH  for  










Table 1. Influence of type of desolvating agent on the particle size. (30 µL of 
glutaraldehyde was used as cross-linking agent at 50°C temperatures). 
 
Protein Desolvating agent Particle size (nm) 
-Lactalbumin Acetone 213 










preparing the nanoparticles.  Figure 3 show the effect of 
temperature on nanoparticle size. It can be concluded 
that as the temperature increased the particle size was 
decreased and preparation at 50°C produced significantly 












smaller particles. The particle sizes of 256, 149 and 108 






Controlled drug delivery technology represents one of the 
frontier areas of science, which involves multidisciplinary 
scientific approach, contributing to human health care. 
Whey proteins have interesting functional property and 
can be used as nanoparticles systems for encapsulation 
and controlled delivery application. Since -lactalbumin is 
a milk protein, it will be fairly easy to apply in foods and 
pharmaceutics. It can be anticipated that -lactalbumin 
the second most abundant protein in the whey fraction of 
bovine milk, can be induced to form nanoparticles.  
Therefore, fabrication of -lactalbumin nanoparticles as 
a drug and food delivery system was investigated herein. 
The nanoparticles size prepared from -lactalbumin was 
influenced by several process variables including pH, 
agitation speed, temperature, etc. In predetermined con-
ditions (protein concentration of 25 mg.ml-1), the particle 
was prepared at 50°C, pH 2.5 and agitation rate of 500 
rpm. To the best of our knowledge, the current paper is 
the first discussing potential of -lactalbumin nanoparti-
cles as delivery system and deserves further study. Op-
timization of this fabrication method for manufacturing -
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